Physician profile
Kisha Long
NPI 1992943021
$11,052.84
in general payments reported to CMS, 2019-2025
41 companies · $2,656 in 2025
The $2,656 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,456 · 2022: $2,351 · 2023: $2,352 · 2024: $2,238 · 2025: $2,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,319 · Consulting Fee: $648 · Education: $155 · Honoraria: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,319.09 |
| Consulting Fee | $647.50 |
| Education | $154.90 |
| Honoraria | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,780.47 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $1,193.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,135.28 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,055.76 | 2021-2025 | Dupixent |
| Genzyme Corporation | $712.67 | 2021-2025 | |
| Optinose US, INC. | $367.22 | 2021-2025 | |
| Genentech USA, INC. | $359.20 | 2021-2025 | Xolair, Tecentriq |
| Abbvie INC. | $343.28 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $329.07 | 2021-2025 | Cuvitru, Takhzyro |
| Grifols USA, LLC | $309.47 | 2021-2025 | Xembify |
| Aimmune Therapeutics, INC. | $278.58 | 2022-2024 | |
| Amgen INC. | $275.19 | 2022-2025 | Tezspire |
| Pfizer INC. | $258.90 | 2021-2025 | |
| Covis Pharma Gmbh | $251.98 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $234.89 | 2022-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $232.21 | 2021-2024 | Auvi-Q |
| Leo Pharma INC. | $173.05 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $155.74 | 2024-2025 | Nemluvio |
| Ars Pharmaceuticals Operations, INC. | $151.65 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $143.23 | 2023-2024 | Ryaltris |
| Alk-Abello, INC | $137.31 | 2022-2025 | Timothy, Standardized, Standardized Mite D. Farinae, Pre-Pen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.56 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Csl Behring | $132.48 | 2021-2023 | Hizentra |
| Organon LLC | $119.43 | 2025 | Vtama |
| Teva Pharmaceuticals USA, INC. | $118.66 | 2021-2023 | |
| Phadia US INC. | $92.75 | 2022-2024 | Immunocap |
| Octapharma USA, INC. | $80.44 | 2021-2022 | |
| Incyte Corporation | $79.67 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $60.90 | 2024-2025 | Ebglyss |
| Blueprint Medicines Corporation | $52.75 | 2023-2024 | Ayvakit |
| Regeneron Pharmaceuticals, INC. | $44.06 | 2023-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $42.63 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $36.45 | 2021-2024 | Orladeyo |
| Aytu Biopharma, INC. | $33.85 | 2021-2024 | Karbinal |
| Greer Laboratories, INC. | $27.63 | 2024 | Palforzia |
| Pharming Healthcare, INC. | $25.06 | 2024 | Ruconest |
| Gc Biopharma USA, INC. | $23.47 | 2024 | Alyglo |
| Uswm, LLC | $20.17 | 2021 | |
| Neos Therapeutics, LP | $17.86 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.97 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.77 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kisha Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.